Healthcare
Tenaya Therapeutics, Inc.(TNYA)
Live Price
Offline$0.731
+2.67% today
1Y Change
+28.66%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $120.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +55.0%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tenaya Therapeutics, Inc. (TNYA) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $0.73 and up 28.7% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +55.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +55.0%, free cash flow +24.7% with operating margin 0.0% and ROIC -69.4%. Stock Foundry combines TNYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +55.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -10.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -2.6% | -15.8% | -25.0% |
2026 Mar 11, 2026 | +7.7% | +4.0% | -4.2% | -13.8% |
2025 Nov 10, 2025 | +20.0% | -0.7% | -11.9% | -1.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNYA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TNYA Max Drawdown
-73.81%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNYA and SPY.
Company Overview
Tenaya Therapeutics, Inc.
NASDAQ Global Select
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
- Leadership
- Faraz Ali
- IPO Date
- Jul 30, 2021
- Employees
- 97
- Street Address
- 171 Oyster Point Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 825 6900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 0.9
Growth
- Revenue
- 0.0%
- EPS
- +55.0%
- Free Cash Flow
- +24.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -85.2%
- ROIC
- -69.4%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 6.84
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.